restructuring

The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs. 

Facing questions over data security in the US and Ireland, the company has changed its name as it looks to shed its China operations.

CEO Margo Georgiadis said that the company has "seen a slowdown in consumer demand across the entire DNA category."

The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.

Roche said the layoffs at its Madison, Wisconsin site will start Dec. 31 and continue through June 30, 2020.

Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.

The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.

The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments. 

The restructuring and job cuts are expected to save the firm more than $70 million annually. 

Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.